- Home
- SNN vs EXEL Comparison
SNN vs EXEL Comparison
Compare SNN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- EXEL
- Stock Information
- Founded
- SNN 1856
- EXEL 1994
- Country
- SNN United Kingdom
- EXEL United States
- Employees
- SNN N/A
- EXEL N/A
- Industry
- SNN Industrial Specialties
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNN Health Care
- EXEL Health Care
- Exchange
- SNN Nasdaq
- EXEL Nasdaq
- Market Cap
- SNN 12.7B
- EXEL 11.3B
- IPO Year
- SNN 1999
- EXEL 2000
- Fundamental
- Price
- SNN $28.83
- EXEL $40.37
- Analyst Decision
- SNN Hold
- EXEL Buy
- Analyst Count
- SNN 3
- EXEL 18
- Target Price
- SNN $27.50
- EXEL $39.59
- AVG Volume (30 Days)
- SNN 801.1K
- EXEL 2.8M
- Earning Date
- SNN 07-31-2025
- EXEL 08-05-2025
- Dividend Yield
- SNN 2.60%
- EXEL N/A
- EPS Growth
- SNN 56.15
- EXEL 237.58
- EPS
- SNN 0.47
- EXEL 2.20
- Revenue
- SNN $5,810,000,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- SNN $6.87
- EXEL $9.37
- Revenue Next Year
- SNN $5.19
- EXEL $11.05
- P/E Ratio
- SNN $30.88
- EXEL $18.32
- Revenue Growth
- SNN 4.70
- EXEL 24.49
- 52 Week Low
- SNN $23.69
- EXEL $21.36
- 52 Week High
- SNN $31.72
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- SNN 49.61
- EXEL 42.39
- Support Level
- SNN $28.40
- EXEL $41.03
- Resistance Level
- SNN $30.38
- EXEL $42.07
- Average True Range (ATR)
- SNN 0.36
- EXEL 0.95
- MACD
- SNN -0.17
- EXEL -0.42
- Stochastic Oscillator
- SNN 30.00
- EXEL 12.85
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.